Zydus to launch mirabegron extended-release tablets in the USA
Indian generics major Zydus Lifesciences (NYSE: ZYDUSLIFE) today announced the launch of mirabegron extended-release tablets, 25mg in the US market.
The company had earlier received final approval from the US Food and Drug Administration (FDA) to market extended release mirabegron tablets USP 25mg and 50mg, a generic version of Myrbetriq extended-release tablets). Zydus is among the first suppliers to launch the generic version of mirabegron the US market and is prepared to launch the product imminently.
Myrbetriq was developed and is marketed by Japan’s Astellas Pharma (TYO: 4503), which last year lost a patent dispute, when the US District Court for the District of Delaware issued a decision finding that the company’s Patent No 10,842 on Myrbetriq (mirabegron), which expires in March 2030, is invalid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze